VCYT vs. RDNT, FLGT, VRDN, PROG, GH, CSTL, NTRA, SUPN, TNDM, and PCRX
Should you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include RadNet (RDNT), Fulgent Genetics (FLGT), Viridian Therapeutics (VRDN), Progenity (PROG), Guardant Health (GH), Castle Biosciences (CSTL), Natera (NTRA), Supernus Pharmaceuticals (SUPN), Tandem Diabetes Care (TNDM), and Pacira BioSciences (PCRX). These companies are all part of the "medical" sector.
Veracyte vs.
Veracyte (NASDAQ:VCYT) and RadNet (NASDAQ:RDNT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
RadNet has higher revenue and earnings than Veracyte. RadNet is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
68.3% of RadNet shares are held by institutional investors. 2.9% of Veracyte shares are held by insiders. Comparatively, 5.1% of RadNet shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Veracyte and Veracyte both had 6 articles in the media. Veracyte's average media sentiment score of 1.51 beat RadNet's score of 0.64 indicating that Veracyte is being referred to more favorably in the media.
Veracyte presently has a consensus price target of $30.20, indicating a potential upside of 18.06%. RadNet has a consensus price target of $30.00, indicating a potential upside of 3.73%. Given Veracyte's higher probable upside, equities research analysts plainly believe Veracyte is more favorable than RadNet.
Veracyte has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, RadNet has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.
Veracyte received 88 more outperform votes than RadNet when rated by MarketBeat users. Likewise, 73.14% of users gave Veracyte an outperform vote while only 67.20% of users gave RadNet an outperform vote.
RadNet has a net margin of -0.90% compared to Veracyte's net margin of -9.70%. RadNet's return on equity of 3.28% beat Veracyte's return on equity.
Summary
RadNet beats Veracyte on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Veracyte Competitors List
Related Companies and Tools